AIxCrypto Holdings, Inc. (AIXC): Nasdaq/NYSE listing notice — Qualigen receives Nasdaq deficiency notice for late Q1 10-Q; delisting hearing set

AIxCrypto Holdings, Inc.

Nasdaq notified Qualigen on May 19, 2025 of failure to timely file Form 10-Q for quarter ended March 31, 2025.
Deficiency under Listing Rule 5250(c)(1) will be considered by the Hearings Panel as additional delisting basis.
Company has a previously scheduled hearing and intends to present its compliance plan.
No assurance that the Panel will grant an extension or that Qualigen will ultimately regain compliance.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AIxCrypto Holdings, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

May 19, 2025, Qualigen Therapeutics, Inc. (the “Company”) received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on May 19, 2025 (the “Notice”). The Notice indicated that the Nasdaq Hearings Panel (the “Panel”) will consider the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market . This matter serves as an additional deficiency under Nasdaq Listing Rule 5250(c)(1), which require

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AIxCrypto Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-011530

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.